Acura Pharmaceuticals
ACUR
ACUR was delisted on the 22nd of February, 2017.
27 hedge funds and large institutions have $11.6M invested in Acura Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 5 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
28% more capital invested
Capital invested by funds: $9.01M → $11.6M (+$2.57M)
0% more funds holding
Funds holding: 27 → 27 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$168K |
| 2 |
Renaissance Technologies
New York
|
+$40.5K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$39.4K |
| 4 |
SIM
Spark Investment Management
New York
|
+$29.2K |
| 5 |
Goldman Sachs
New York
|
+$9.29K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EWM
Essex Woodlands Management
The Woodlands,
Texas
|
-$343K |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$34K |
| 3 |
Mariner
Overland Park,
Kansas
|
-$16.6K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$8.73K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
-$8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFA
26
BlackRock Fund Advisors
San Francisco,
California
| – | -$34K | -8,522 | Closed |
|
|
27
HighTower Advisors
Chicago,
Illinois
| – | -$8K | -2,120 | Closed |
|
|
BIM
28
BlackRock Investment Management
Wilmington,
Delaware
| – | -$3K | -763 | Closed |
|
29
Simplex Trading
Chicago,
Illinois
| – | +$415 | +100 | New |
|
ACUR Hedge Fund Activity: Q2 2015 in Review
27 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Acura Pharmaceuticals (ACUR) for Q2 2015, worth a combined $11.6M — up 28% from $9.01M a quarter earlier.
Fund positioning in ACUR was balanced in Q2 2015: 5 funds opened new positions, 5 closed out, 7 added to existing stakes and 5 trimmed.
The largest buyer was Jacobs Levy Equity Management, adding an estimated $168K. The largest seller was Essex Woodlands Management, cutting an estimated $343K.
- 27 institutional investors held Acura Pharmaceuticals (ACUR) as of Q2 2015, unchanged from Q1 2015.
- Funds reported $11.6M of Acura Pharmaceuticals stock for Q2 2015, up 28% quarter-over-quarter.
- 5 funds opened new Acura Pharmaceuticals positions in Q2 2015 and 5 closed out, a net change of 0 holders.
- The largest Acura Pharmaceuticals buyer in Q2 2015 was Jacobs Levy Equity Management, an estimated $168K added.
- The largest Acura Pharmaceuticals seller in Q2 2015 was Essex Woodlands Management, an estimated $343K sold.
Based on aggregated 13F filings for Q2 2015.